Investor Overview

• Arena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs.
• Our internally discovered and developed drug for weight management, BELVIQ® (lorcaserin HCl), was launched in the United States in 2013 and approved in South Korea in early 2015. Following are links to certain additional information:
  
   
  

   

  • www.belviq.com
  • Full Prescribing Information
   

• We have granted exclusive marketing and distribution rights for BELVIQ to Eisai Inc. and Eisai Co., Ltd., for most territories worldwide; to Ildong Pharmaceutical Co., Ltd., for South Korea; to CY Biotech Company Limited for Taiwan; and to Teva Pharmaceutical Industries Ltd.’s local Israeli subsidiary for Israel.

• We will explore with our collaborators or independently BELVIQ’s therapeutic potential for additional indications, in other formulations and in combination with other drugs.

• We are utilizing our validated research and development approach to advance our pipeline of internally discovered, oral drug candidates.

Frequently Asked Questions